

Lupin announces licensing deal with Sandoz for Ranibizumab biosimilar

12 August 2025 | News

Lupin will be responsible for manufacturing the product and for regulatory submissions



Mumbai-based Lupin Limited has partnered with Sandoz Group AG, Switzerland, to market and commercialise Lupin's biosimilar ranibizumab across multiple regions.

Under the terms of the agreement, Sandoz will oversee commercialisation of the product across the European Union (excluding Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, and Malaysia.

Lupin will be responsible for manufacturing the product and for regulatory submissions. Sandoz will hold exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it will have semi-exclusive marketing rights.

Pursuant to another agreement executed between the two companies, Sandoz will acquire sole rights for commercialisation of Lupin's biosimilar ranibizumab in Canada, while Lupin will manage its manufacture and regulatory filings.

Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Proliferative Diabetic Retinopathy (PDR), and Choroidal Neovascularisation (CNV).

“We are delighted to partner with Sandoz for the launch and commercialization of ranibizumab in multiple markets globally,” said Thierry Volle, President EMEA and Emerging Markets, Lupin. “This partnership underscores our shared vision to expand global access to cutting-edge biologic therapies and improve outcomes for underserved patients.”